[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"upper-gastrointestinal-bleeding\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:upper-gastrointestinal-bleeding":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,76,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100643768","acute-kidney-injury-in-upper-gi-bleeding-patients-100643768",false,"NCT07636083","Acute Kidney Injury in Upper GI Bleeding Patients","Acute Kidney Injury Following Upper Gastrointestinal Bleeding: Incidence and Predictors","Inclusion Criteria:\n\n* Adult patients aged 18 years or older\n* Patients presenting with clinical features suggestive of acute upper gastrointestinal bleeding (UGIB), including hematemesis, coffee-ground vomiting, or melena\n* Diagnosis of UGIB confirmed by upper gastrointestinal endoscopy or strong clinical evidence when endoscopy is not immediately available\n* Patients admitted to Sohag University Hospitals (medical wards or intensive care unit)\n* Availability of renal function data, including at least one serum creatinine measurement at admission and serial measurements during hospitalization\n* Availability of baseline renal function (previous serum creatinine within 3-12 months) or estimable baseline during hospitalization\n\nExclusion Criteria:\n\n* Patients with end-stage renal disease (ESRD) on chronic dialysis\n* Patients with a history of renal transplantation\n* Patients with advanced chronic kidney disease stage 5 (eGFR \\\u003C15 mL\u002Fmin\u002F1.73 m²) not on dialysis\n* Patients with lower gastrointestinal bleeding\n* Patients with incomplete or missing essential renal function data\n* Patients discharged or deceased within 24 hours of hospital admission\n* Pregnant patients\n* Patients with acute kidney injury at presentation due to causes other than UGIB","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate the incidence of acute kidney injury (AKI) among patients presenting with acute upper gastrointestinal bleeding (UGIB) at Sohag University Hospitals, and to identify predictors associated with renal impairment in these patients.",[24,25],"Upper Gastrointestinal Bleeding","Acute Kidney Injury",[27,28,29,30,31,32,33,34],"UGIB","AKI","Renal Impairment","Gastrointestinal Hemorrhage","Serum Creatinine","Kidney Function","Variceal Bleeding","Non-variceal Bleeding","NOT_YET_RECRUITING","2026-06-04",{"date":38,"type":39},"2026-06-09","ACTUAL",{"date":41,"type":20},"2026-05-15",{"date":43,"type":20},"2027-05-15",{"name":45,"class":46},"Sohag University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100431756","otsc-vs-angiographic-embolization-in-patients-with-refractory-non-variceal-upper-gastrointestinal-bleeding-100431756","NCT04902248","OTSC vs. Angiographic Embolization in Patients With Refractory Non-variceal Upper Gastrointestinal Bleeding","Endoscopic Application of Over-the-scope Clips (OTSC) vs. Angiographic Embolization in Patients With Refractory Non-variceal Upper Gastrointestinal Bleeding: a Multicenter Randomized Comparison","Inclusion Criteria:\n\n* 1\\. Patients presented with overt signs of acute upper gastrointestinal bleeding (hematemesis, melena and\u002For hypotension) 2. documented bleeding lesion at endoscopy (ulcer, dieulafoy's lesion and others), further bleeds (persistent or recurrent) after endoscopic hemostasis (thermal or hemoclips) as defined by an International Consensus Group\n\nExclusion Criteria:\n\n1. without a full informed consent from the patient or his next of kin\n2. Age \\\u003C18 years\n3. Pregnant\n4. Lactating women\n5. patients with known allergy to intravenous contrast",{"count":56,"type":20},236,"INTERVENTIONAL",[59],"NA","In the management of patients with acute upper non-variceal upper gastrointestinal bleeding, further bleeding is the most important adverse factor predictive of mortality. In the United Kingdom Audit on acute upper gastrointestinal bleeding, clinical evidence of further bleeding was reported in 13% of patients following the first endoscopy and 27% of them died. The use of OTSC has emerged as an alternative before angiographic embolization(TAE) which is often considered most definitive.\n\nWe propose to define the algorithm in the management of patients with refractory bleeding from their peptic ulcers or other non variceal causes. We hypothesize that endoscopic use of OTSC compares favourably with TAE and both lead to similar outcomes. An equivalence of the two modalities may mean that endoscopic application of OTSC should be attempted before TAE as often we need to document further bleeds with endoscopy and a second treatment should be instituted at the same time.",[24],[63,64],"Over-the-scope clips","angiographic embolization","RECRUITING","2026-03-16",{"date":68,"type":39},"2026-03-18",{"date":70,"type":39},"2021-11-27",{"date":72,"type":20},"2026-11-30",{"name":74,"class":46},"Chinese University of Hong Kong",5,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":91,"leadSponsor":93,"locationsCount":47},"100601711","halp-as-a-novel-score-for-prediction-of-mortality-and-rebleeding-in-upper-git-bleeding-100601711","NCT07114042","HALP as a Novel Score for Prediction of Mortality and re_bleeding in Upper GIT Bleeding","Moglobin, Albumin, Lymphocyte and Platelet Score as a Novel Predictor of Mortality and Re-bleeding in Patients With Upper Gastrointestinal Bleeding","Inclusion Criteria:\n\n* Patients will be included if they were initially admitted to the emergency department, had a confirmed diagnosis of upper gastrointestinal bleeding via endoscopy, and were 18 years of age or older.\n\nExclusion Criteria:\n\n* Incomplete clinical data.\n* Lack of laboratory results obtained at emergency department admission necessary for the calculation of HALP score; albumin, hemoglobin (HGB), platelets (PLT), or international normalized ratio (INR).\n* Pregnancy\n* Patients with missing data on clinical outcomes",{"count":84,"type":20},100,"Evaluation of the prognostic utility of the HALP score in patients with upper gastrointestinal bleeding, particularly in predicting re\\_bleeding risk and mortality in internal medicine department in Sohag University Hospitals.",[24],"2025-08-08",{"date":89,"type":39},"2025-08-11",{"date":87,"type":20},{"date":92,"type":20},"2026-02",{"name":45,"class":46},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":57,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":47},"100584980","purastat-combined-with-adrenaline-versus-standard-of-care-in-upper-gastrointestinal-bleeding-100584980","NCT06896409","PuraStat® Combined With Adrenaline Versus Standard of Care in Upper Gastrointestinal Bleeding","PuraStat® Combined With Adrenaline Versus Standard of Care in Non-variceal Upper Gastrointestinal Bleeding. Multicentric International Clinical Trial.","Inclusion Criteria:\n\n* Age \\>18 years\n* Undergoing endoscopic therapy for non-variceal gastrointestinal bleeding\n\nExclusion Criteria:\n\n* Variceal or portal hypertension-related gastrointestinal bleeding\n* Lack of signed consent form\n* Pregnancy or breastfeeding",{"count":102,"type":20},126,[59],"PuraStat® is a novel gel that offers several advantages over traditional hemostatic powders. Its transparency allows for continuous visualization of the bleeding site, and it can be applied in narrow spaces or in combination with other treatments. Additionally, the pre-filled syringe design ensures ease of handling and precise delivery.\n\nMost published data on PuraStat® as a hemostatic agent originates from surgical settings. In endoscopy, its primary applications have been in polypectomy-related hemostasis and the promotion of wound healing. Reports indicate a hemostasis success rate of 90.4%, with a recurrence rate of 10.4%.\n\nLimited data exist regarding the efficacy of PuraStat® as a hemostatic agent in upper gastrointestinal bleeding (UGIB) lesions. This study hypothesizes that PuraStat®, when combined with Adrenaline, serves as a feasible and effective first-line treatment for gastrointestinal bleeding. To evaluate this, a prospective, randomized, parallel-group, open-label clinical trial is proposed.",[24],"2025-03-25",{"date":108,"type":39},"2025-03-26",{"date":110,"type":39},"2023-10-01",{"date":112,"type":20},"2025-10",{"name":114,"class":46},"Tallaght University Hospital"]